About this trial
Current guidelines advocate that ARVC patients, typically young and active individuals with a significant history of competitive endurance sports, cease endurance training in favour of activities with low cardiac burden such as bowling and golf. Empirically, it is often suggested that heart rate during exercise should not exceed 100-120 bpm in these patients, but these guidelines are arbitrary and not scientifically based. In practice, it is estimated that up to 50% of patients do not comply with these recommendations .
Adequate quantification of the arrhythmogenic burden, defined as premature ventricular beats in proportion to all heart beats in each period of time, and cardiac load (defined as stroke volume for volume load and systolic blood pressure for pressure load) experienced by ARVC patients when performing different types of physical exercise would be a first step towards designing a safe and effective intervention so that these patients can profit from an active life style.
This study therefore aims to quantify and describe the arrhythmogenic burden and cardiac load experienced by patients with ARVC while performing different physical exercise over a range of intensities - all strictly within the range currently recommended by different cardiological societies.
Eligibility criteria
Qualifiers
Definitive ARVC diagnosis according to the modified 2010 ARVC Task Force Criteria
Pathogenic / likely pathogenic variant in one of the following desmosomal genes: plakophilin-2 (PKP-2), desmoglein-2 (DSG-2) or desmoplakin (DSP) or gene-elusive definite ARVC (i.e., genetic test performed but no pathogenic / likely pathogenic variant found)
Control group: diagnosed ischemic heart disease with ejection fraction above 35%
Agreement with responsible primary cardiologist that study participation is not considered beyond acceptable levels of physical activity for this particular patient
Disqualifiers
No genetic test history for ARVC variants
Heart failure with severely reduced left ventricular ejection fraction (LVEF <35%)
For women: Pregnancy, breastfeeding, or intention to become pregnant during the study.
Known or suspected non-compliance, drug, or alcohol abuse
Trial design
Treatments tested in this trial
- Exercise
Treatment groups
Sponsors and collaborators
Swiss Federal Institute of Technology
Lead sponsor
University of Zurich
Collaborator